Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance ... that is specific to the subcutaneous form. In a statement, Eisai and Biogen said ...

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.